Of exocytosis. This inhibitor of exocytosis was designed to target NSF | Plikli CMS
1
Of exocytosis. This inhibitor of exocytosis was designed to target NSF, a critical component of the exocytic machinery (16?8). We developed a fusion polypeptide with two domains, a TAT domain, which enters cells through macropinocytosis, and an NSF domain that inhibits NSF. This fusion peptide, designated TAT-NSF222, inhibits NSF ATPase activity, decreases endothelial exocytosis, and blocks inflam

Comments

Who Upvoted this Story

What is Plikli?

Plikli is an open source content management system that lets you easily create your own user-powered website.

Latest Comments